Autoinflammatory diseases

EQS-News: Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases

Retrieved on: 
Thursday, July 6, 2023
Asos, Asthma, Central nervous system, University, Chronic kidney disease, Arthritis, Fever, NOMID, FCAS, Survival, Autoinflammatory diseases, NLRP3, Quality of life, MWS, University of California, San Diego Performance-Based Skills Assessment, Inflammation, Life expectancy, CAPS, Journal of Immunology, Inflammatory bowel disease, Hyperkinesia, Skin, Journal, Patient, NLR, Fatty liver disease, ASO, Weight gain, Fine chemical, Vaccine, Pharmaceutical industry

Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.

Key Points: 
  • Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.
  • CAPS are a spectrum of autoinflammatory diseases caused by activating mutations in the NLRP3 gene.
  • The activity of NLRP3-ASO was tested in an in vivo NOMID disease model; NOMID is the most severe form of CAPS.
  • After systemic ASO treatment, life expectancy was significantly increased, with weight gains and reductions in the severity of skin lesions, showing an overall reduction in systemic inflammation.

ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis

Retrieved on: 
Thursday, May 25, 2023
ASC, JIA, Frontiers in Medicine, Macrophage, Serum, Autoinflammatory diseases, Research, Juvenile idiopathic arthritis, Super Meat Boy, Monocyte, ANA, Patient, Joint, Therapy, Autoimmunity, Autoantibody, Vaccine, Medicine

In the paper titled, “Inflammasome activation and formation of ASC specks in patients with juvenile idiopathic arthritis,” the authors reported the following:

Key Points: 
  • In the paper titled, “Inflammasome activation and formation of ASC specks in patients with juvenile idiopathic arthritis,” the authors reported the following:
    Il-1β production from macrophages exposed to extracellular ASC specks was enhanced in serum of JIA patients with a high titer of ANA, suggesting that autoantibodies favor a secondary inflammatory response to ASC specks by macrophages
    The authors stated, “We clearly discovered direct inflammasome activity ex vivo in CD14+ CD16− monocytes of oligo- and poly-articular JIA patients.” To read the article, Click Here .
  • “The research published in Frontiers in Medicine demonstrates the role of inflammasome activation in two of the most common types of JIA, oligo- and poly-articular, which were previously thought to be classical antigen-driven autoimmune conditions.
  • This research provides support for the broad range of conditions that are impacted by activation of the innate immune response,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
  • “Additionally, the data demonstrating enhanced IL-1β production from macrophages exposed to extracellular ASC specks in JIA patients with a high titer of ANA supports the potential of ASC speck inhibition in helping to control inflammation in this population.”

BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

Retrieved on: 
Wednesday, May 10, 2023
Storm, Life, Atlas, Pathology, Phagocytosis, Massachusetts General Hospital, MBA, Harvard Medical School, Autoimmunity, Harvard University, Georgetown University, Eye, Wharton School of the University of Pennsylvania, Patient, Castleman Disease Collaborative Network, The New York Times, Faculty, Merck, Laboratory, Infection, BS, University, Research, EPA, Hematology, Hospital, Bacteria, FDA, Vaccine, NIH, Tufts University, Yale School of Medicine, Cancer, NLRP3, Biomarker, Hospital of the University of Pennsylvania, Public health, Publication, Saipan, Master of Science, Merck & Co., Therapy, Inflammation, Q&A, Autoinflammatory diseases, Penn, Internal medicine, Infectious Diseases Society of America, Immunosuppression, Gene, Flexner Report, GMA, Pharmaceutical industry, Nursing, MD, Brigham, FIDSA

The webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases.

Key Points: 
  • The webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases.
  • The major scientific breakthrough in identifying genes responsible for autoinflammatory diseases and related genotypes.
  • Key biomarkers for autoinflammatory diseases and new targets for treatments, like the NLRP3 inflammasome.
  • A live Q&A discussion with key opinion leader, David Fajgenbaum, MD, will follow the presentation.

AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH

Retrieved on: 
Tuesday, March 7, 2023
Data, HLH, Patient, Autoinflammatory diseases, Caregiver, IL18, Safety, Pharmaceutical industry, Medical device

The study is designed to show the efficacy and safety of Tadekinig alfa (r-hIL-18BP) for the treatment of primary monogenic IL-18 driven HLH, an ultra-rare and life-threatening condition with no approved therapies, mainly affecting children.

Key Points: 
  • The study is designed to show the efficacy and safety of Tadekinig alfa (r-hIL-18BP) for the treatment of primary monogenic IL-18 driven HLH, an ultra-rare and life-threatening condition with no approved therapies, mainly affecting children.
  • “This is a truly exciting time as we pioneer development of the first targeted treatment option for IL18 driven diseases and conditions,” said Dr. Djordje Filipovic, CEO of AB2 Bio.
  • “We are pleased to have completed the targeted enrollment in this pivotal study which represents a significant milestone for AB2 Bio and the patient community.
  • “Tadekinig alfa is an important potential new treatment option for patients suffering from IL-18 driven autoinflammatory diseases with no current standard of care.